Kintara Therapeutics (KTRA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kintara Therapeutics has corrected its previous announcement regarding the issuance of Contingent Value Rights (CVRs) related to its planned merger with TuHURA Biosciences. The CVRs will now be issued to stockholders immediately before a planned reverse stock split, aligning with the upcoming merger scheduled for October 18, 2024.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
